Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of this study is to demonstrate the beneficial effects on gut microbiota composition and activity of the diary intake of insoluble fiber (extract from Aspergillus Niger) for three weeks. The first studies about the fiber have shown a favorable gut microbiota modulation and an improvement of metabolic parameters like LDL cholesterol. In addition to fecal measurements, several biomarkers of colic fermentation will be assessed: expired gases, PolyUnsaturated Fatty Acid, Short Chain Fatty Acid (SCFA) after a rich-fiber breakfast (= 15 grams) and a nutritional challenge test at lunch. The gastrointestinal tolerance of fiber intake and the intestinal transit modification will be also followed during all the study.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Chitin-Glucan supplementation | Experimental |
| |
| Placebo supplementation | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Kiotransine (chitin-glucan from aspergillus niger) | Dietary Supplement | The volunteers will take three times a day one bag of powder containing 1.5g of chitin-glucan fiber during three weeks. The powder will be diluted in water. |
| Measure | Description | Time Frame |
|---|---|---|
| Fecal SCFA | Change from baseline fecal SCFA at three weeks by Gas chromatography-Flame Ionization Detector | baseline and three weeks |
| Measure | Description | Time Frame |
|---|---|---|
| gut microbiota composition | Change from baseline gut microbiota composition by 16SrDNA Illimina Sequencing | baseline and three weeks |
| fecal biliary acids | Change from baseline fecal biliary acids by FAME quantification (gas-liquid chromatography) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Centre de Recherche en Nutrition Humaine Rhône-Alpes - Centre hospitalier Lyon Sud | Pierre-Bénite | 69310 | France |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 35614185 | Result | Ranaivo H, Zhang Z, Alligier M, Van Den Berghe L, Sothier M, Lambert-Porcheron S, Feugier N, Cuerq C, Machon C, Neyrinck AM, Seethaler B, Rodriguez J, Roumain M, Muccioli GG, Maquet V, Laville M, Bischoff SC, Walter J, Delzenne NM, Nazare JA. Chitin-glucan supplementation improved postprandial metabolism and altered gut microbiota in subjects at cardiometabolic risk in a randomized trial. Sci Rep. 2022 May 25;12(1):8830. doi: 10.1038/s41598-022-12920-z. |
| Label | URL |
|---|---|
| Related Info | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Dietary Supplement | The volunteers will take three times a day one bag of powder containing placebo during three weeks. The powder will be diluted in water. |
|
| baseline and three weeks |
| fecal PolyUnsaturated Fatty Acids (PUFA) | Change from baseline fecal PolyUnsaturted Fatty Acids (PUFA) by FAME quantification (gas-liquid chromatography) | baseline and three weeks |
| fecal albumin | Change from baseline fecal albumin by immunoenzymatic technique (ELISA) | baseline and three weeks |
| fecal zonulin | Change from baseline fecal zonulin by immunoenzymatic technique (IDK Zonulin ELISA) | baseline and three weeks |
| fecal calprotectin | Change from baseline fecal calprotectin by Phadia 100 system | baseline and three weeks |
| TLR-agonist in stool | Change from baseline TRL-agonist in stool using the HEK-Blue™ TLR cellules | baseline and three weeks |
| Change from baseline CO2, CH4 and H2 kinetics in exhaled gases | by gas chromatography, during ten hours after rich-fiber breakfast and nutritional challenge test at lunch | baseline and three weeks |
| body composition | Change from baseline bodycompositio by bioimpedancemetry | baseline and three weeks |
| Change from plasma glucose kinetics | by spectrophotometry method , during seven hours after rich-fiber breakfast and nutritional challenge test at lunch | baseline and three weeks |
| Change from plasma insulin kinetics | by radio-immuno analysis , during seven hours after rich-fiber breakfast and nutritional challenge test at lunch | baseline and three weeks |
| Change from plasma Non-Esterifies Fatty-Acid (NEFA) kinetics | by spectrophotometry method , during seven hours after rich-fiber breakfast and nutritional challenge test at lunch | baseline and three weeks |
| plasma TriacylGlycerol (TG) kinetics | Change from plasma TriacylGlycerol (TG) kinetics by spectrophotometry method , during seven hours after rich-fiber breakfast and nutritional challenge test at lunch | baseline and three weeks |
| Cholesterol Total, Cholesterol LDL | Change from baseline cholesterol Total, Cholesterol LDL by spectrophotometry method | baseline and three weeks |
| resting energy expenditure | Change from baseline resting energy expenditure by indirect calorimetry | baseline and three weeks |
| stool consistency | by Bristol Stool Chart (type1-7) | every week, up to three weeks |
| stool frequency | by questionnaire | every week, up to three weeks |
| gastro-intestinal symptoms | by questionnaires and visual analogue scale (VAS) score (on a 90mm horizontal line; from no symptom (minimal) to serious symptom (maximum)) | every week, up to three weeks |
| quality of life during the study | change from baseline quality of life during the study by SF 36 questionnaire | baseline and three weeks |
| change from baseline dietary intake of fibre | by three day food record | baseline and three weeks |
| ID | Term |
|---|---|
| D056128 | Obesity, Abdominal |
| ID | Term |
|---|---|
| D009765 | Obesity |
| D050177 | Overweight |
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |
| D001835 | Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided